Praluent 75 mg Solution for Injection in Pre-Filled Pen

Manufacturer
Sanofi-Aventis Deutschland GmbH
 
Contents
Alirocumab
 
Indication
Heterozygous familial hypercholesterolaemia, Mixed dyslipidaemia, Nonfamilial hypercholesterolaemia
 
Instruction
Administer via Subcutaneous.
 
Drug interaction
Increased target-mediated clearance and reduced systemic plasma concentration with statins and other lipid-lowering agents (e.g. ezetimibe, fenofibrate).